Stocks and Investing Stocks and Investing
Wed, November 27, 2019
Tue, November 26, 2019
Mon, November 25, 2019
Fri, November 22, 2019
Thu, November 21, 2019
Wed, November 20, 2019
Tue, November 19, 2019

Alethia Young Maintained (VRTX) at Buy with Increased Target to $229 on, Nov 19th, 2019


Published on 2024-10-26 18:25:28 - WOPRAI
  Print publication without navigation


Alethia Young of Cantor Fitzgerald, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $217 to $229 on, Nov 19th, 2019.

Alethia has made no other calls on VRTX in the last 4 months.



There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 1 agrees with Alethia's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Alan Carr of "Needham" Downgraded from Strong Buy to Hold on, Thursday, August 1st, 2019


These are the ratings of the 6 analyists that currently disagree with Alethia


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $250 on, Thursday, October 31st, 2019
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $229 on, Thursday, October 31st, 2019
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $247 on, Thursday, October 31st, 2019
  • Robyn Karnauskas of "Citigroup" Maintained at Strong Buy with Increased Target to $225 on, Tuesday, October 22nd, 2019
  • Ying Huang of "B of A Securities" Initiated at Strong Buy and Held Target at $220 on, Thursday, October 17th, 2019
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $213 on, Thursday, August 1st, 2019